Accessibility Tools
Invert colors
Monochrome
Dark contrast
Light contrast
Low saturation
High saturation
Highlight links
Highlight headings
Screen reader
Read mode
Content scaling
100
%
Font size
100
%
Line height
100
%
Letter spacing
100
%
(678) 384-7220
info@geovax.com
About Us
Company
Leadership
Board of Directors & Corporate Advisors
Scientific Advisory Board
Collaborators
Technology
MVA Technology Overview
Gedeptin® Technology Overview
Publications
Pipeline
Pipeline Summary
Oncology
Infectious Diseases
Clinical Trials
Investors
Corporate Profile
Press Releases
Media
Events & Presentations
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
Careers
Contact
SEC Filings
SEC Filings
Year
2026
Date
04-27
Description
Other Definitive Proxy Statements
SEC Form
DEF 14A
Download Word
Download Excel
Download PDF
id
About GeoVax
Company
Board of Directors & Corporate Advisors
Scientific Advisory Board
Our Technology
MVA Technology Overview
Gedeptin® Technology Overview
Publications
Product Pipeline
Pipeline Summary
Oncology
Infectious Diseases
Investors
Corporate Profile
GeoVax Stock Information
Corporate Governance
Events & Presentations
SUBSCRIBE FOR UPDATES FROM GEOVAX
Register to receive email alerts for GeoVax press releases
SUBMIT
Message
About Us
Company
Leadership
Board of Directors & Corporate Advisors
Scientific Advisory Board
Collaborators
Technology
MVA Technology Overview
Gedeptin® Technology Overview
Publications
Pipeline
Pipeline Summary
Oncology
Infectious Diseases
Clinical Trials
Investors
Corporate Profile
Press Releases
Media
Events & Presentations
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
Careers
Contact
Search
